Cargando…

Significance of programmed death‐ligand 1 expression in resected lung cancer and its relationship with EGFR mutation

BACKGROUND: Several studies have reported that the high expression of programmed death‐ligand 1 (PD‐L1) within tumor cells predicts a poor prognosis. However, the relationship between the PD‐L1 expression and lymph node metastasis or driver mutations in lung cancer remains poorly understood. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osoegawa, Atsushi, Abe, Miyuki, Takumi, Yohei, Hashimoto, Takafumi, Karashima, Takashi, Miyawaki, Michiyo, Sugio, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447166/ https://www.ncbi.nlm.nih.gov/pubmed/37455369 http://dx.doi.org/10.1111/1759-7714.15031

Ejemplares similares

Giant benign intrathoracic schwannoma: a decade-long progression towards fatality
por: Miyawaki, Michiyo, et al.
Publicado: (2023)

Osimertinib as first-line treatment for recurrent lung cancer patients with EGFR mutation
por: Osoegawa, Atsushi, et al.
Publicado: (2023)

Tracheal injury from dog bite in a child
por: Miyawaki, Michiyo, et al.
Publicado: (2023)

Clinical significance of part-solid lung cancer in the eighth edition TNM staging system
por: Okamoto, Tatsuro, et al.
Publicado: (2021)

The clinical manifestations and treatment of male breast cancer: a report of three cases
por: Suehiro, Shuji, et al.
Publicado: (2015)

Resection and postoperative radiation therapy for desmoid fibromatosis of the chest wall in a young woman
por: Noda, Daiki, et al.
Publicado: (2021)

The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer
por: Takeuchi, Hideya, et al.
Publicado: (2017)

Elevated red cell distribution width to platelet count ratio predicts poor prognosis in patients with breast cancer
por: Takeuchi, Hideya, et al.
Publicado: (2019)

Thymoma-associated myasthenia gravis coexisting with myotonic dystrophy: a case report
por: Miyawaki, Michiyo, et al.
Publicado: (2021)

Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4‐ALK fusion gene
por: Kometani, Takuro, et al.
Publicado: (2018)

Aspergillus Nodule in a Patient With Autoimmune Pulmonary Alveolar Proteinosis
por: Nagaoka, Yuhei, et al.
Publicado: (2022)

Adenomyoepithelioma of the breast coexisting with ductal carcinoma in situ: a case report and review of the literature
por: Kamei, Mirei, et al.
Publicado: (2015)

Cancer-associated retinopathy after surgery for breast cancer: a case report and review of the literature
por: Kamei, Mirei, et al.
Publicado: (2018)

The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma
por: Wu, Shafei, et al.
Publicado: (2017)

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
por: Osoegawa, Atsushi, et al.
Publicado: (2021)

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
por: Masuda, Takeshi, et al.
Publicado: (2023)

The significance of programed cell death‐ligand 1 expression in vestibular schwannoma
por: Lee, Se A, et al.
Publicado: (2023)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Status and physiological significance of circulating adiponectin in the very old and centenarians: an observational study
por: Sasaki, Takashi, et al.
Publicado: (2023)

Interactions between programmed death-1 and programmed death ligand-1 promote tolerance by blocking the T cell receptor-induced stop signal
por: Fife, Brian T., et al.
Publicado: (2009)

Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment
por: Hoshimoto, Aitoshi, et al.
Publicado: (2023)

Lymphoma Microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification
por: Miyawaki, Kohta, et al.
Publicado: (2022)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

In-Hospital Deaths From Ambulatory Care–Sensitive Conditions Before and During the COVID-19 Pandemic in Japan
por: Abe, Kazuhiro, et al.
Publicado: (2023)

Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy
por: Tanizaki, Junko, et al.
Publicado: (2023)

Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients
por: Yun, Sumi, et al.
Publicado: (2019)

Programmed death ligand‐1 expression in gastrointestinal cancer: Clinical significance and future challenges
por: Yamashita, Kohei, et al.
Publicado: (2020)

Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
por: Tominaga, Tetsuro, et al.
Publicado: (2019)

Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma
por: Song, Zhengbo, et al.
Publicado: (2016)

Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients
por: Chen, Jun, et al.
Publicado: (2017)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

A critical role for the programmed death ligand 1 in fetomaternal tolerance
por: Guleria, Indira, et al.
Publicado: (2005)

The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
por: Kang, Minsu, et al.
Publicado: (2021)

Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer
por: Zhang, Ying, et al.
Publicado: (2017)

Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma
por: Mikami, Shuji, et al.
Publicado: (2019)

Prognostic Significance of the Dynamic Change of Programmed Death-ligand 1 Expression in Patients with Multiple Myeloma
por: Guan, Jian, et al.
Publicado: (2019)

Receiving the home care service offered by certified care workers prior to a patients’ death and the probability of a home death: observational research using an instrumental variable method from Japan
por: Abe, Kazuhiro, et al.
Publicado: (2019)

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
por: Zhang, Yang, et al.
Publicado: (2014)

Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_58aetq2sp0tkqmbc02tjrtsrdo